The better outcomes observed in ER+ BCs having high AR expression may be attributed to the ability of AR signaling to consistently inhibit the basal and estrogen-induced proliferation and survival of ER+ BC cell lines [43,44,45]. Here, ESR1 is linked to breast cancer.